Galphas-coupled receptor signaling actively down-regulates α4β1-integrin affinity: A possible mechanism for cell de-adhesion by Chigaev, Alexandre et al.
BioMed  Central
Page 1 of 16
(page number not for citation purposes)
BMC Immunology
Open Access Research article
Galphas-coupled receptor signaling actively down-regulates 
α4β1-integrin affinity: A possible mechanism for cell de-adhesion
Alexandre Chigaev*1,2, Anna Waller2, Or Amit2 and Larry A Sklar*1,2
Address: 1Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA and 2Cancer Research and 
Treatment Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
Email: Alexandre Chigaev* - achigaev@salud.unm.edu; Anna Waller - awaller@salud.unm.edu; Or Amit - oamit@salud.unm.edu; 
Larry A Sklar* - lsklar@salud.unm.edu
* Corresponding authors    
Abstract
Background: Activation of integrins in response to inside-out signaling serves as a basis for
leukocyte arrest on endothelium, and migration of immune cells. Integrin-dependent adhesion is
controlled by the conformational state of the molecule (i.e. change in the affinity for the ligand and
molecular unbending (extension)), which is regulated by seven-transmembrane Guanine nucleotide
binding Protein-Coupled Receptors (GPCRs). α4β1-integrin (CD49d/CD29, Very Late Antigen-4,
VLA-4) is expressed on leukocytes, hematopoietic stem cells, hematopoietic cancer cells, and
others. Affinity and extension of VLA-4 are both rapidly up-regulated by inside-out signaling
through several Gαi-coupled GPCRs. The goal of the current report was to study the effect of Gαs-
coupled GPCRs upon integrin activation.
Results: Using real-time fluorescent ligand binding to assess affinity and a FRET based assay to
probe α4β1-integrin unbending, we show that two Gαs-coupled GPCRs (H2-histamine receptor
and β2-adrenergic receptor) as well as several cAMP agonists can rapidly down modulate the
affinity of VLA-4 activated through two Gαi-coupled receptors (CXCR4 and FPR) in U937 cells and
primary human peripheral blood monocytes. This down-modulation can be blocked by receptor-
specific antagonists. The Gαs-induced responses were not associated with changes in the
expression level of the Gαi-coupled receptors. In contrast, the molecular unbending of VLA-4 was
not significantly affected by Gαs-coupled GPCR signaling. In a VLA-4/VCAM-1-specific myeloid cell
adhesion system, inhibition of the VLA-4 affinity change by Gαs-coupled GPCR had a statistically
significant effect upon cell aggregation.
Conclusion: We conclude that Gαs-coupled GPCRs can rapidly down modulate the affinity state
of VLA-4 binding pocket through a cAMP dependent pathway. This plays an essential role in the
regulation of cell adhesion. We discuss several possible implications of this described phenomenon.
Background
Integrins, one of the largest families of cell adhesion mol-
ecules play an important role in the regulation of immune
responses and leukocyte traffic, development, hemostasis,
and cancer [1]. A unique feature of integrins is in their
ability to rapidly and reversibly regulate cell adhesion,
and thereby modulate cell recruitment and homing, with-
out a significant change in the expression of the molecule.
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Understanding the molecular mechanisms that regulate
rapid changes in cell adhesion avidity is essential, since
integrins are known to play roles in many human dis-
eases. They represent an attractive target for several exist-
ing and emerging drugs for treatment of inflammatory
diseases, anti-angiogenic cancer therapy, anti-thrombotic
therapy, and others [2-5].
α4β1-integrin (CD49d/CD29, Very Late Antigen-4, VLA-4)
is expressed on peripheral blood leukocytes, hematopoi-
etic progenitors/stem cells, hematopoietic cancer cells,
and others [6-8]. On circulating lymphocytes, VLA-4 has
the potential to exist in multiple affinity states that can
mediate tethering, rolling, and arrest on a ligand (CD106,
Vascular Cell Adhesion Molecule-1, VCAM-1) that is up-
regulated on inflamed endothelia [9,10]. The ability of
leukocytes to arrest, extravasate, and navigate is directly
related to the activation of VLA-4 integrin through Gαi-
coupled GPCRs. Classical chemoattractants and chemok-
ines that include formyl peptide and SDF-1 (CXCL12) are
examples of Gαi-coupled GPCR ligands [11]. Gαi-coupled
GPCRs activate integrin by triggering an inside-out signal-
ing pathway. The change in the affinity for the ligand as
well as the unbending (extension) of the integrin mole-
cule are believed to be a part of this activation process [12-
14].
We have developed a VLA-4 specific fluorescent probe that
allows us to monitor VLA-4 affinity changes in real-time
on live cells. Our model cell line is undifferentiated U937
cells, which do not attach to plastic surfaces nor exhibit
homotypic adhesion [15], and constitutively express VLA-
4 integrins in a low affinity state [6]. In these undifferen-
tiated U937 cells VLA-4 affinity was rapidly and tran-
siently triggered by several different Gαi-coupled
receptors, and the kinetics of the affinity change reflected
the desensitization kinetics of a particular GPCR [6].
Moreover, in a VLA-4/VCAM-1 specific cell adhesion sys-
tem, the time course of avidity changes in response to
receptor activation coincided with the time course of the
affinity changes [16]. The increased cell aggregation could
be accounted for by VLA-4 affinity changes rather than
integrin clustering or increasing number of VLA-4/VCAM-
1 bonds [17]. Using the same VLA-4 specific fluorescent
probe, we have also developed a FRET based assay for the
detection of VLA-4 unbending (extension) upon inside-
out activation [18], which was validated in a series of pub-
lications [19-21]. We found that rather than being intrin-
sically related to the affinity change of the integrin
binding pocket, the conformational unbending of the
VLA-4 molecule is regulated by a different signaling path-
way, in a different temporal fashion [20].
Recently, it has been proposed that in addition to well-
known pro-adhesive signaling events (modulated by Gαi-
coupled GPCRs), anti-adhesive signaling events can par-
ticipate in regulation of cell adhesion, diapedesis and
chemotaxis [11]. We noted previously that anti-inflam-
matory signals could be derived from Gαs-coupled signal-
ing pathway [22], and recently that U-73122, a suspected
histamine analog [23], could inhibit the VLA-4 affinity
increase [20]. The goal of the current work was to explore
whether the Gαs-coupled GPCR related pathway can affect
the affinity or conformational state of the integrin. We
found that two Gαs-coupled receptors constitutively
expressed on U937 cells can actively down regulate VLA-4
affinity, after activation through two Gαi-coupled GPCRs.
This affinity down regulation was not modulated by the
change in the intracellular Ca2+ concentration. Further-
more, the unbending of VLA-4 integrin, as detected using
the FRET based assay, was not significantly affected by
Gαs/cAMP signaling pathway. Using a VLA-4/VCAM-1-
specific myeloid cell adhesion model system, we found
that blocking the integrin affinity change by the activation
of the Gαs/cAMP signaling pathway had a statistically sig-
nificant effect upon cell adhesion. However, we also
detected an activation of cell adhesion by Gαi-coupled
GPCR under these conditions (when the affinity change
was blocked). In the absence of the affinity change a rapid
increase in cell adhesion was attributed to the unbending
(extension) of the integrin molecule.
Results
Signaling through Gαs-coupled receptors blocks Gαi-
coupled receptor-induced VLA-4 affinity up-regulation
The LDV-FITC probe, which mimics binding of a natural
ligand to VLA-4, was used to study the effect of Gαs-cou-
pled receptor signaling on the VLA-4 affinity change.
Because the concentration of the LDV-FITC probe in these
experiments (4 nM) has been chosen to be lower than Kd
for the resting state of VLA-4 and higher than the Kd for the
activated state, the transition from the low to the high
affinity state was accompanied by additional binding of
the probe. As shown previously, activation of Gαi-coupled
GPCRs leads to up-regulation of VLA-4 affinity, and the
LDV-FITC binding kinetics reflects the activation kinetics
for a particular GPCR. LDV-FITC binding is rapid and
transient for wild type receptors (because of the receptor
desensitization), and rapid and sustained for a non-
desensitizing mutant of FPR [6].
To study the effect of Gαs-coupled receptors we took
advantage of two Gαs-coupled receptors that constitu-
tively expressed on U937 cells: histamine H2 receptor and
β2 adrenergic receptors [24,25]. U937 cells stably trans-
fected with CXCR4 receptor, preincubated with 4 nM
LDV-FITC, were treated with receptor-specific agonists at
saturating concentration (amthamine or isoproterenol)
and DMSO (control). Next, cells were activated with
CXCL12 (SDF-1). While control cells showed rapid andBMC Immunology 2008, 9:26 http://www.biomedcentral.com/1471-2172/9/26
Page 3 of 16
(page number not for citation purposes)
transient activation of VLA-4, cells preactivated through
Gαs-coupled receptor showed a significantly lower
response (Fig. 1A). Although, a slight decrease in the LDV-
FITC binding to the resting cells after Gαs-coupled recep-
tor stimulation was observed, amthamine or isoprotere-
nol alone did not affect the resting VLA-4 affinity as
measured by dissociation rate analysis (data not shown).
The majority of integrin molecules on resting U937 cells
exhibit low affinity (see Fig. 5 in [6]), however a small
population of high affinity sites that cannot be detected
by a dissociation rate analysis could exists. Gαs-coupled
receptor signalling can eliminate this small fraction of
active integrins.
The use of a non-desensitizing mutant of FPR allowed us
to study the effect of Gαs-coupled activation in real-time.
In the absence of Gαi-coupled GPCR desensitization,
VLA-4 maintained its high affinity state for a longer period
of time [6,19]. Addition of specific Gαs-coupled receptor
ligands in this case led to a dose dependent down regula-
tion of integrin affinity that was reflected in the rapid dis-
sociation of the LDV-FITC probe (Fig. 1B). Thus,
according to the analysis of LDV-FITC ligand binding,
activation of Gαs-coupled GPCRs prevents VLA-4 affinity
up-regulation, if done prior to Gαi-coupled receptor sign-
aling, or it rapidly down regulates VLA-4 affinity, if per-
formed during continuous Gαi-coupled receptor
signaling.
The effect of Gαs-coupled receptor agonists is reversed by 
specific receptor antagonists
Next, to verify whether the observed effects are receptor-
specific, we used two specific Gαs-coupled receptor antag-
onists: tiotidine (histamine H2 receptor antagonist), and
ICI-118,551 (β2 adrenergic receptor antagonist) [26,27].
Addition of receptor antagonists after U937 cells were
treated with Gαs-coupled receptor agonist completely
reversed a suppressive effect of Gαs-coupled receptor sign-
aling (blue lines, Fig. 2A,B). In this case, at the end of the
experiment the binding of the LDV-FITC probe returned
back to the level of the untreated control (red lines,
labeled fMLFF only, Fig. 2A,B). It is worth noting that Gαs-
coupled receptor antagonists by themselves did not have
any effect on fMLFF activated samples (see Fig. 2B, black
line labeled fMLFF, ICI-118,551), nor did they activate
VLA-4 when added alone (data not shown). Thus, Gαs-
coupled receptors provide a signal that results in VLA-4
affinity down regulation, and this effect is receptor specific
since specific receptor antagonists reversed the effects of
Gαs-coupled receptor agonists.
Binding and dissociation of the LDV-FITC probe in response  to Gαs-coupled receptor agonists Figure 1
Binding and dissociation of the LDV-FITC probe in 
response to Gαs-coupled receptor agonists. Experi-
ments were conducted as described under "Methods". A, 
LDV-FITC probe binding and dissociation on U937 cells sta-
bly transfected with CXCR4 receptor plotted as mean chan-
nel fluorescence (MCF) versus time. The experiment 
involved sequential additions of Gαs-coupled receptor lig-
ands (isoproterenol (100 nM) or amthamine (500 nM)), then, 
fluorescent LDV-FITC probe (4 nM, below saturation, added 
3 min prior to addition of Gαi-coupled receptor ligands). 
Control cells were treated with vehicle (DMSO). Next, cells 
were activated with SDF-1 (25 nM, arrows). Rapid and 
reversible binding of the probe reflects VLA-4 affinity change 
[6]. Curves are means out of two independent runs calcu-
lated on a point-by-point basis. B, LDV-FITC probe binding 
and dissociation on U937 cells stably transfected with the 
non-desensitizing mutant of FPR (ΔST) [33] plotted as mean 
channel fluorescence (MCF) versus time. The experiment 
involved sequential additions of fluorescent LDV-FITC probe 
(4 nM), fMLFF (100 nM), and different concentrations of 
amthamine, or DMSO (control) (arrows). The MCF value 
corresponding to cell autofluorescence is indicated by the 
horizontal arrow. One representative experiment out of 
three experiments is shown. Experiments shown in the dif-
ferent panels were performed using different instruments, 
and therefore MCF values are not identical.
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Dissociation rate analysis confirmed that changes in the 
LDV-FITC probe binding could be attributed to the change 
in the affinity of the binding pocket
For different affinity states of VLA-4, the equilibrium dis-
sociation constant (Kd) of the LDV-FITC probe varied
inversely with the dissociation rate constant (koff), sug-
gesting that the association rate constant was essentially
independent of receptor conformation [6,10]. Therefore,
we routinely use dissociation rate analysis to quantita-
tively probe the affinity state of the VLA-4 binding pocket.
Cells were preincubated with a higher concentration of
LDV-FITC (25 nM) to saturate the majority of low affinity
sites. Next, a large excess of the unlabeled LDV competitor
is added to initiate a dissociation of labeled probe. After
Binding and dissociation of the LDV-FITC probe in response to Gαs-coupled receptor agonists and antagonists Figure 2
Binding and dissociation of the LDV-FITC probe in response to Gαs-coupled receptor agonists and antagonists. 
A, B, The effect of Gαs-coupled receptor antagonists. U937 cells stably transfected with the non-desensitizing mutant of FPR 
were sequentially treated with the LDV-FITC probe (4 nM, below saturation), fMLFF (100 nM), and A, amthamine (500 nM), 
tiotodine (10 μM), or B, isoproterenol (1 nM), ICI-118,551 (10 μM). B, Additional control sample was treated with the same 
concentration of LDV-FITC, fMLFF, and ICI-118,551 without addition of isoproterenol to show the effect of Gαs-coupled 
receptor antagonist without addition of the agonist. The MCF value corresponding to cell autofluorescence is indicated by the 
horizontal arrow. Data are plotted as MCF versus time. One representative experiment out of three experiments is shown. 
C,D, Kinetic analysis of binding and dissociation of LDV-FITC probe on U937 cells stably transfected with the non-desensitizing 
mutant of FPR. Cells were sequentially treated with the LDV-FITC probe (25 nM, near saturation), Gαi-coupled receptor lig-
and (fMLFF, 100 nM), Gαs-coupled receptor ligands, C, amthamine (500 nM), or D, isoproterenol (100 nM). At time points 
indicated by arrows, cells were treated with excess unlabeled LDV containing small molecule (2 μM), and the dissociation of 
the fluorescent molecule was followed. Dissociation rate constants (koff) were obtained by fitting dissociation curves to a single 
exponential decay equation (as described in the text). Experiments shown in the different panels were performed using differ-
ent instruments, and therefore MCF values are not identical.
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activation through Gαi-coupled GPCR, little additional
binding of the probe was seen (since the Kd for the low
affinity state is ~12 nM (Table I in [6]), at 25 nM ~70% of
sites are occupied before activation) (Fig. 2C,D). At rest,
the majority of VLA-4 molecules present on U937 cells
exhibit the low affinity state (koff~0.1–0.05 s-1). After Gαi-
coupled receptor activation by fMLFF the dissociation rate
was significantly slower (koff~0.01–0.025 s-1, slower koff
indicates higher affinity). After additional stimulation
through two different Gαs-coupled receptors, dissociation
rates were comparable to the rate at the resting state. These
koff values for the resting and activated VLA-4 receptor
were quantitatively similar to previously published data
[6]. Thus, the analysis of dissociation rates at rest, after
Gαi-coupled receptor activation, and after Gαs-coupled
receptor stimulation indicated that the Gαs-coupled
receptor related signaling pathway is decreasing VLA-4
affinity by increasing the dissociation rate of the ligand.
Gαs-coupled receptor activation has no significant effect 
upon expression of Gαi-coupled receptors and VLA-4 
integrin
Next, in order to exclude the possibility that stimulation
of Gαs-coupled receptors dramatically changes surface
expression of Gαi-coupled receptors and VLA-4, U937
cells were treated with Gαs-coupled receptor agonists, and
fMLFF in a manner that was identical to experiments
described above (Fig. 1, 2). Then, cells were stained with
anti-CXCR4, anti-FPR, and anti-CD49d antibodies (Fig.
3). No statistically significant changes in a surface expres-
sion were detected. Thus, the effect of down-regulation of
integrin affinity is not related to the expression of Gαi-
coupled GPCRs or VLA-4 integrin itself.
Earlier data suggest that FPR signalling typically requires
occupancy of a fraction of the receptor sites [28]. In our
experiments with saturating ligand concentration termi-
nation of signaling is expected to require a significant
down-modulation of receptor expression within a few
minutes. Furthermore, the ability of Gαs-coupled receptor
antagonists to completely reverse the effect of Gαs-cou-
pled receptor agonists (Fig. 2A, B, blue lines) indicates
that integrin affinity down-regulation is triggered by the
Gαs-coupled GPCRs activation rather than by Gαi-cou-
pled deactivation. In addition, the use of the non-desensi-
tizing FPR mutant emphasizes the role of Gαs-coupled
signalling in the down-regulation of integrin affinity.
Forskolin and dbcAMP mimic the effect of Gαs-coupled 
receptor signaling
Gαs-coupled receptors are well known to activate adenylyl
cyclase, which increases the concentration of intracellular
cyclic adenosine monophosphate (cAMP). Also, treat-
ment of U937 cells with β-adrenoceptor agonist induced
a several fold elevation of intracellular cAMP concentra-
tion [29]. Therefore, we have tested whether activation of
adenylyl cyclase by forskolin or dibutyryl cAMP would
mimic the effects of Gαs-coupled receptors activation on
VLA-4 affinity regulation. We found that preincubation of
U937 cells with either compound abolished VLA-4 affin-
ity up-regulation induced through CXCR4 receptor (Fig.
4A). We also detected affinity down regulation in real-
time after activation of U937 cells through a non-desensi-
tizing mutant of FPR (Fig. 4B,C). It is worth noting that
the overall kinetics of the LDV-FITC ligand binding and
dissociation in these cases was comparable to the case of
Gαs-coupled receptor activation (compare Fig. 1 and Fig.
4). Thus, our data suggest that the down regulation of
VLA-4 affinity after Gαs-coupled receptor activation is
modulated by the increased concentration of cAMP.
Signaling through Gαs-coupled receptors does not block 
VLA-4 unbending (extension)
A second aspect of integrin activation through "inside-
out" signaling is a large conformational change, which
results in the molecular unbending (extension) of the
molecule, and has been associated with cell rolling [30].
The unbent integrin conformation results in faster cell
aggregation rates, potentially because of the accessibility
of the VLA-4 binding site [20]. Moreover, according to our
recent findings, VLA-4 molecular extension is regulated by
a mechanism, independent of a regulation of the affinity
for the ligand [20]. Therefore, we studied the effect of Gαs-
coupled receptor signaling on integrin extension using the
FRET based real-time unbending assay (Fig. 5) [18-20].
Activation of U937 cell through a non-desensitizing
mutant of FPR results in the rapid and sustained
unquenching of the fluorescent signal, which is inter-
preted as a change in the distance of closest approach
between the surface of the plasma membrane and the
headgroup of the integrin molecule (molecular unbend-
ing) (see Methods and Fig. 1 in [18], or Fig. 5 in [19]).
Addition of Gαs-coupled receptor ligands resulted in a
rapid decrease of the fluorescent signal to about 40–50%
of the control within ~60 seconds. Thereafter, the fluores-
cent signal slowly recovered back to ~70–90% of the con-
trol at the end of the experiment for the case of histamine
H2 receptor simulation (Fig. 5A,B). The recovery phase
was less definitive for the case of β2 adrenergic receptor
stimulation (data not shown). Thus, the overall kinetics of
the affinity change as detected by LDV-FITC probe bind-
ing and dissociation was entirely different from the kinet-
ics of the molecular unbending as detected using FRET
(compare Figs. 1, 2, 4 and Fig. 5A,B). In the case of the
affinity change it takes up to 10 min to reach "full deacti-
vation". The signal returns to the baseline value at 200–
800 s after the beginning of the experiment, and no signif-
icant recovery was observed at this time scale (see Fig. 1B,
Fig. 2A,B, Fig. 4B,C). In contrast, for the FRET signal, theBMC Immunology 2008, 9:26 http://www.biomedcentral.com/1471-2172/9/26
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Effect of Gαs-coupled receptor activation upon surface expression of CXCR4 receptor, formyl peptide receptor, and VLA-4 Figure 3
Effect of Gαs-coupled receptor activation upon surface expression of CXCR4 receptor, formyl peptide recep-
tor, and VLA-4. U937 cells were treated with vehicle (untreated control), amthamine, isoproterenol, or sequentially with 
fMLFF, and vehicle (untreated control), amthamine or isoproterenol as described for experiments shown in Fig. 1 and 2. Next, 
cells were placed on ice and stained with anti-CXCR4 antibodies, A, anti-FPR antibodies, B, or CD49d antibodies, C. Histo-
grams and bar graphs of mean channel fluorescence (MCF) ± SEM (n = 3) for unstained cell (autofluorescence), nonspecific 
binding (isotype control), treated with vehicle (untreated), and treated with different ligands are shown. One representative 
experiment out of two experiments is shown. * indicates means are not significantly different (P > 0.05) as calculated by one-
way ANOVA analysis using GraphPad Prism software.
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response was maximal at ~1 min after Gαs-coupled recep-
tor activation, and the signal did not return back to the
baseline as in the case of the affinity change. This partial
quenching result does not distinguish whether all VLA-4
molecules were still partially unbent (intermediate
extended state) or whether a fraction of the VLA-4 mole-
cules was still fully extended, while the rest of the integrins
returned back to the bent conformation. However, the dif-
ferent kinetics of the FRET change and LDV-FITC binding
support the idea that unbending and affinity are regulated
though different signaling mechanisms [20].
Next, to study the effect of a sustained elevation of cAMP
concentration upon integrin unbending we preincubated
U937 with forskolin (10 μM for 5 min). This treatment
was sufficient to completely inhibit (Fig. 4A) or reverse
(Fig. 4B) the effect of Gαi-coupled receptors activation
upon VLA-4 affinity up-regulation. However, we could
not find any statistically significant difference in the FRET
based real-time unbending assay between forskolin
treated and DMSO (vehicle) treated cells (Fig. 5C,D).
Thus, a sustained elevation of cAMP by forskolin had no
effect upon VLA-4 unbending after Gαi-coupled receptor
activation.
The effect of Gαs-coupled receptor on VLA-4 activation is 
independent of Ca2+-signaling
Conformational unbending of VLA-4 is dependent on the
elevation of cytosolic Ca2+ concentration, while affinity
up-regulation can be observed in the absence of Ca2+
increase [20]. Therefore, we tested whether in our model
system Gαs-coupled receptor activation would signifi-
cantly change intracellular Ca2+-concentration (Fig. 6).
Activation through a non-desensitizing mutant of FPR
resulted in sustained elevation of intracellular Ca2+. None
of the Gαs-coupled receptor agonists significantly lowered
the intracellular Ca2+  concentration. In fact, we have
observed a small increase of intracellular Ca2+  after
amthamine treatment (Fig. 6B). Thus, activation of Gαs-
coupled receptors decreased VLA-4 affinity without signif-
icantly changing (decreasing) intracellular Ca2+-concen-
tration.
These data additionally support the finding that the affin-
ity state of the binding pocket is largely independent of
cytoplasmic Ca2+ level (Fig. 2 in [20]). Furthermore, par-
tial quenching of the FRET signal (Fig. 5B) together with
elevated intracellular Ca2+ (Fig. 6) is analogous to the pre-
viously described condition, which arises several minutes
after wild type Gαi-coupled receptor activation. There, the
affinity state was already low because of rapid receptor
desensitization, while VLA-4 integrins remained partially
extended, as detected in the FRET based assay (see Fig. 7
in [20]).
Binding and dissociation of the LDV-FITC probe in response  to cAMP agonists Figure 4
Binding and dissociation of the LDV-FITC probe in 
response to cAMP agonists. A, LDV-FITC probe binding 
and dissociation on U937 cells stably transfected with 
CXCR4 receptor plotted as mean channel fluorescence 
(MCF) versus time. Prior to SDF-1 addition, cells were prein-
cubated with forskolin (40 μM), dibutyryl-cAMP (2 mM), or 
DMSO (control) for 10 min at 37°C. Next, cells were prein-
cubated wth 4 nM LDV-FITC, and treated with SDF-1 (25 
nM). Mean and standard error of mean are shown (n = 3). B, 
C, LDV-FITC probe binding and dissociation on U937 cells 
stably transfected with the non-desensitizing mutant of FPR 
plotted as mean channel fluorescence (MCF) versus time. 
After sequential additions of fluorescent LDV-FITC probe (4 
nM), and fMLFF (100 nM), cells were treated with B, forskolin 
(10 μM), C, different concentration of dibutyryl-cAMP, or 
DMSO (control). The MCF value corresponding to cell 
autofluorescence is indicated by the horizontal arrow. One 
representative experiment out of three experiments is 
shown.
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The effect of Gαs/cAMP signaling pathway activation upon 
cell adhesion
Next, to study the implications of the Gαs-coupled signal-
ing pathway on VLA-4 dependent cell adhesion we uti-
lized a VLA-4/VCAM-1-specific real-time cell adhesion
assay. The specificity of cell aggregation was tested using
anti-α4 integrin mAb (HP2/1) [16] as well as the unla-
beled LDV small molecule that completely blocked cell
Energy transfer, on U937 cells stably transfected with the non-desensitizing mutant of FPR, between the LDV-FITC donor  probe and octadecylrhodamine (R18) acceptor probe Figure 5
Energy transfer, on U937 cells stably transfected with the non-desensitizing mutant of FPR, between the LDV-
FITC donor probe and octadecylrhodamine (R18) acceptor probe. Experiments were conducted as described under 
"Methods", and in [18,19]. A, Cells were preincubated at 37°C with 100 nM LDV-FITC probe to saturate high and low affinity 
sites. Next, LDV-FITC fluorescence was quenched after addition of octadecyl rhodamine (R18, 10 μM). Then, cells were acti-
vated by addition of fMLFF (100 nM). Data are plotted as MCF versus time for three conditions: quenched and then activated by 
Gαi-coupled receptor agonist (fMLFF (solid line)), quenched, then activated by Gαi-coupled receptor agonist (fMLFF) and then 
activated by Gαs-coupled receptor agonist (amthamine, 500 nM (dashed line)), and quenched only (R18 only, DMSO vehicle, 
dotted line). B, Data from panel A were re-plotted by subtracting the baseline data (R18 only) from activated cell data. The 
data are normalized assuming that average MCF value for FPR activated cells is equal to 100%; therefore, the Y-axis is labeled 
as "Donor fluorescence, % relative to fMLFF". As shown previously, activation of the cells transfected with the non-desensitiz-
ing mutant of FPR [18] led to the rapid unquenching of the FITC signal, which was interpreted as a change in the distance of 
closest approach between the VLA-4 ligand binding site occupied by LDV-FITC and the membrane surface (so called unbending 
or extension of the integrin molecule, see Fig. 1 in [18], or Fig. 5C in [19]). Curves are means out of five independent runs cal-
culated on a point-by-point basis. C, Cells were preincubated for 5 min at 37°C with 10 μM of forskolin or DMSO (control). 
Next, cells were stained with 100 nM LDV-FITC probe and fluorescence was quenched after addition of octadecyl rhodamine 
(R18, 10 μM). Cells were activated by addition of 100 nM fMLFF, or DMSO (control). Notice the absence of the difference 
between forskolin treated (forskolin/fMLFF) and DMSO treated (DMSO/fMLFF) cells after addition of fMLFF. Mean and stand-
ard error of mean are shown (n = 3). D, Data from panel C were re-plotted as described for panel B.
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aggregation ([20] and Fig. 7A, solid squares). Prior to mix-
ing, pre-stained (red, PKH26GL) U937 cells, stably trans-
fected with non-desensitizing mutant of FPR, were treated
with forskolin (20 μM, 10 min, 37°C). This treatment was
sufficient to fully block/reverse the effect of Gαi-coupled
receptors on the VLA-4 affinity change (Fig. 4A,B). How-
ever, it was insufficient to completely prevent rapid cellu-
lar aggregation induced by fMLFF (Fig. 7A, compare open
and solid triangles after 5 min). A decrease in the number
of free singlets in the media (singlets depletion) results
from an increase in the number of aggregates, i.e. aggrega-
tion. It is worthwhile noting that we were also able to
detect a statistically significant difference between forsko-
lin treated and vehicle (DMSO) treated cells after fMLFF
activation (Fig. 7A, compare open triangles and solid cir-
cles). Similar data were obtained using Gαs-coupled
receptor activation (data not shown). This suggests that
the cAMP pathway was able to reduce the potential of cells
to form aggregates in response to Gαi-coupled receptor
activation.
Kinetics of intracellular Ca2+ response, detected using Indo-1, AM, in U937 cells stably transfected with the non-desensitizing  mutant of FPR in response to activation by Gαi/Gαs-coupled receptor agonists Figure 6
Kinetics of intracellular Ca2+ response, detected using Indo-1, AM, in U937 cells stably transfected with the 
non-desensitizing mutant of FPR in response to activation by Gαi/Gαs-coupled receptor agonists. Experiments 
were conducted as described under "Methods". A, Control cells loaded with Indo-1 were treated with fMLFF (100 nM) and 
DMSO. B, Cells were sequentially treated with fMLFF (100 nM) and amthamine (500 nM); C, cells were treated with fMLFF 
(100 nM) and isoproterenol (100 nM); D, cells were treated with fMLFF and Forskolin (40 μM). One representative experi-
ment out of three experiments is shown.
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Since Gαs/cAMP signaling pathway blocks only one aspect
of integrin activation, the affinity state of VLA-4 binding
pocket, the difference between forskolin treated/fMLFF
activated (open triangles) and untreated/fMLFF activated
samples (solid circles) appears to be attributable to the
impact of the affinity change on cell aggregation. The dif-
ference between unstimulated cells (solid triangles) and
forskolin pretreated cells after fMLFF stimulation (open
triangles) appears to be attributable to molecular unbend-
ing (extension).
The effect of Gαs/cAMP signaling pathway activation
upon cell aggregation can be also observed in real-time
(Fig. 7B). Addition of forskolin to cellular aggregates
formed after fMLFF activation resulted in an increase in
the number of free U937 singlets (Fig. 7B, compare solid
and open circles after second addition). An increase in the
number of free singlets in the media is interpreted as a
decrease in a number of aggregates, i.e. disaggregation.
Thus, rapid down regulation of VLA-4 affinity through
Gαs/cAMP signaling pathway plays an important role in
the regulation of VLA-4/VCAM-1 specific cell adhesion.
VLA-4 affinity down-modulation can be detected on 
peripheral blood monocytes
Finally, to confirm that VLA-4 affinity down regulation
can be detected in primary cells, we have used purified
human peripheral blood monocytes. Monocytes express
CXCR4 and FPR receptors. Rapid and transient binding of
LDV-FITC can be observed in response to cell activation
through these GPCRs [31]. Because, monocytes also
express the β2-adrenergic receptor, we have used isoprot-
erenol as Gas-coupled receptor ligand. Experiments were
performed in a manner identical to Fig. 1A. Human
peripheral blood monocytes pretreated for 2.5 min with
saturating isoproterenol had significantly reduced ampli-
tude of LDV-FITC binding response after addition of SDF-
1 (Fig. 8A), and fMLFF (Fig. 8B). In addition, pretreatment
with isoproterenol affected the resting monocytes, result-
ing in lower LDV-FITC binding. These results were very
similar to U937 cells (compare Fig. 1A and Fig. 8A). Thus,
the effect of Gαs-dependent affinity down regulation of
VLA-4 can be observed on human peripheral blood
monocytes.
As shown previously, the number of α4-integrin mole-
cules detected on peripheral blood cells is significantly
lower than on the cell lines, which represents a less-differ-
entiated phenotype. On peripheral blood human mono-
cytes we have detected only ~6,000 sites. For U937 cells,
we estimated about 40,000–100,000 sites [6]. Therefore,
the overall signal from LDV-FITC on monocytes is ~10
fold lower than for U937 cells.
Changes in cell adhesion between U937 FPR (ΔST) and  VCAM-1-transfected B78H1 cells at resting state and in  response to receptor stimulation Figure 7
Changes in cell adhesion between U937 FPR (ΔST) 
and VCAM-1-transfected B78H1 cells at resting state 
and in response to receptor stimulation. A, U937 FPR 
(ΔST) cells were preincubated for 10 min at 37°C with for-
skolin (20 μM), or DMSO (vehicle). Cells were stimulated 
(arrow) with fMLFF (100 nM), or DMSO (vehicle). Data are 
plotted as % of U937 FPR (ΔST) singlets versus time. Five dif-
ferent experimental conditions are shown: Block/DMSO 
(preincubation with blocking 2 μM LDV small molecule (addi-
tion of DMSO, 1 μl), DMSO/DMSO, resting state (preincuba-
tion with DMSO/addition of DMSO), Forsk/DMSO 
(preincubation with forskolin/addition of DMSO), Forsk/
fMLFF (preincubation with 20 μM forskolin/stimulation with 
100 nM fMLFF), DMSO/fMLFF (preincubation with DMSO, 
stimulation with 100 nM fMLFF). The non-desensitizing FPR 
mutant is used to maintain VLA-4 in a state of constant high 
affinity. Mean and standard error of mean of three independ-
ent experiments are shown (n = 3). Bars on the right side of 
the panel indicate a relative contribution of affinity and 
extension in the overall cell adhesion. B, Effect of forskolin 
addition on adhesion in real-time. Cells were stimulated with 
fMLFF, or DMSO (1st addition). Next, forskolin (20 μM) was 
added. Representative experiment out of two experiments is 
shown.
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Discussion
LDV-FITC probe
The VLA-4 specific fluorescent probe was based on a
highly specific α4β1-integrin inhibitor BIO1211, which
contains the Leu-Asp-Val (LDV) ligand binding motif
from the alternatively spliced connecting segment-1 (CS-
1) peptide of cellular fibronectin [10,32]. Because car-
boxy-terminal amino acids did not affect ligand binding
affinity (see Table 1 in [32]), they were replaced with Pro-
Ala-Ala-Lys-FITC. This resulted in a fluorescent probe that
we used to study VLA-4 integrin affinity/conformational
changes in a conventional flow cytometer. One of the
major advantages of this probe is that because of its low
molecular weight, diffusion-limited rates of binding allow
binding of the probe on the time scale relevant to
dynamic cell responses. Therefore, this probe can be used
to detect rapid and transient VLA-4-integrin affinity
changes in real-time on live cells [6,16,19,20]. We have
also used this probe to develop a FRET based assay for the
detection of VLA-4 unbending (extension) in real-time
after inside-out activation through GPCRs [18-20].
VLA-4 affinity, extension, and cell adhesion
Previously, we established that affinities of the probe and
native VLA-4 ligand (VCAM-1) vary in parallel when the
integrin affinity state (natural lifetime) is modulated [16].
This affinity modulation results in a rapid change in cell
adhesion efficiency. Moreover, molecular dissociation
rates and cellular disaggregation rates in the absence of
shear are comparable, suggesting that only few bonds are
needed to form cellular aggregates. Therefore, we pro-
posed that the increased aggregation is driven by integrin
affinity changes, and not by clustering of the molecules or
by increased bond numbers [17]. Moreover, using GPCR-
transfected cells, we showed that the time course of avidity
changes in response to the Gαi-coupled receptor activa-
tion coincides with the time course of the affinity changes.
Affinity up-regulation led to rapid cell aggregation [6,16],
and down regulation of affinity and extension resulted in
the cells disaggregation [20].
Here we show that in addition to affinity up-regulation,
the affinity of the VLA-4 binding pocket can be actively
down-regulated, and this down regulation is in response
to the Gαs-coupled receptors/cAMP signaling pathway.
Moreover, affinity down regulation can be seen under
continuous signaling conditions, after cell activation
through a non-desensitizing mutant of Gαi-coupled
GPCR. This mutant is known to produce normal Gαi-cou-
pled signaling, but it cannot be phosphorylated, and thus
Binding and dissociation of the LDV-FITC probe in response to Gαs-coupled receptor agonist Figure 8
Binding and dissociation of the LDV-FITC probe in response to Gαs-coupled receptor agonist. Experiments were 
conducted as described under "Methods". A, LDV-FITC probe binding and dissociation on peripheral blood monocytes plotted 
as mean channel fluorescence (MCF) versus time. The experiment analogous to the one shown in Fig. 1A involved sequential 
additions of Gαs-coupled receptor ligand (isoproterenol (100 nM)) or DMSO (control), next, fluorescent LDV-FITC probe (4 
nM, below saturation, added 2 min prior to addition of Gαi-coupled receptor ligand). Cells were activated with A, SDF-1 (25 
nM, arrow), or B, fMLFF (100 nM, arrow). Rapid and reversible binding of the probe reflects a transient VLA-4 affinity change. 
Curves are means out of four independent runs calculated on a point-by-point basis. One representative experiment out of 
two independent experiments for each ligand is shown. Experiments shown in the different panels were performed using dif-
ferent instruments, and therefore MCF values are not identical.
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it does not desensitize and internalize [33]. As the affinity
of the VLA-4 binding pocket regulates the life-time of the
VLA-4/VCAM bond [17], down regulation of integrin
affinity would decrease the lifetime of the aggregate, and
possibly reduce the transition to firm adhesion.
Another aspect of integrin activation is unbending (or
extension) of the molecule [12,34]. Here we show that
VLA-4 unbending was not inhibited by the Gαs/cAMP sig-
naling pathway. In fact, even in the presence of a high con-
centration of forskolin, which blocked the VLA-4 affinity
change completely, cells were able to respond to fMLFF
activation by rapidly aggregating. This increase in cell
adhesion is interpreted to arise solely from the unbending
of the integrin molecule. Thus, for the first time in this
model system we have established conditions under
which cell adhesion was up-regulated exclusively due to
the extension of the integrin molecule.
The discovery, that affinity of the integrin binding pocket
and the molecular unbending are regulated by two differ-
ent signalling pathways and modulate lifetime of adhe-
sive interaction and cell capture efficiency, has already
been documented [20]. We proposed that the low affinity
unbent conformation represents an ideal rolling confor-
mation (see Fig. 10B in [20]). We postulated that "several
different proteins could participate in the "inside-out"
activation of the integrins; some of them would regulate
affinity, others – the conformational unbending" [20]. It
is possible that affinity regulation by Gαs/cAMP signalling
is directly related to Epac/Rap1 pathway, which is
reported to affect integrin dependent cell adhesion [35].
For integrin unbending the molecular mechanism is still
unclear. However, as shown previously, VLA-4 molecular
unbending requires intracellular Ca2+ increase [20]. Cur-
rent data showed that activation via Gαs-coupled GPCRs
did not significantly decrease intracellular Ca2+ nor affect
molecular unbending. This supports our current model of
integrin conformation regulation in response to "inside-
out" signalling.
Active down regulation of VLA-4 affinity as a possible 
mechanism of cell trafficking
Cancer cell metastasis, role of NK cells
Tumor cell migration is essential in metastasis. As with
hematopoietic progenitor cells, release and homing of cer-
tain cancer cells require adhesion molecules and Gαi-cou-
pled GPCRs (such as VLA-4, CXCL12/CXCR4) [7]. Since
human tissue microarrays showed that 70–90% of breast,
colon, and prostate carcinoma tissues express the β2-
adrenergic receptor [36], these cells may possess the extra-
cellular signaling machinery needed for Gαi/Gαs-coupled
to regulate cell adhesion. It has already been shown that
β2-adrenergic receptor agonist activates, and β2-receptor
antagonist blocks migration of prostate, colon and breast
carcinoma cells in vitro [37-39]. In vivo, a β2-adrenergic
receptor agonist significantly increased lymph node
metastases, while an antagonist inhibited this effect,
tumor growth was not affected by either treatment [36].
Thus, it is possible that down regulation of integrin affin-
ity would significantly change the adhesive properties of
tumor cells, facilitate cell migration/de-adhesion and
lymphatic drainage, and thereby alter their overall meta-
static potential.
NK cells play an important role in tumor cell clearance
and resistance of organs to metastases. To effectively kill
tumor cells, NK cells must localize at tumor sites. The
VLA-4/VCAM-1 interaction is critical for recruitment of
NK cells into lung, liver, and tumor sites [40]. As noted
above, VLA-4 on NK cells exhibits constitutively high
affinity for VCAM-1 as opposed to the low affinity state of
VLA-4 on other circulating leukocytes [41,42]. Under
stress, or treatment with β-adrenergic receptor agonist, a
rapid rise in blood NK cells has been attributed to a reduc-
tion of their adherence to endothelia [43-45]. Since up-
regulation of integrin affinity is essential for firm adhe-
sion on vascular endothelia [9], affinity down-modula-
tion would dramatically affect proper cell localization or
recruitment. Affinity down-regulation could account for
the phenomenon of β-adrenoceptor- or catecholamine-
dependent suppression of NK cell activity, and a decrease
in the overall resistance of an organism to metastasis [46].
Selective recruitment of leukocyte subsets
The multistep paradigm of leukocyte recruitment, where
the interplay between selectins, chemokines, GPCRs, and
integrins determines the specificity of leukocyte recruit-
ment and trafficking, is broadly accepted [11,47-49].
GPCRs, through Gαi coupled inside-out signaling path-
ways, rapidly activate integrins, and trigger integrin
dependent adhesion. Recently, it has been shown that in
addition to pro-adhesive Gαi-coupled GPCRs, anti-adhe-
sive Gαs-coupled receptors can modulate leukocyte
transendothelial migration in vitro and recruitment and
homing in vivo ([11] and references therein). That rapid
affinity down-regulation can account for this modulation
enriches our current understanding of selective recruit-
ment of leukocyte subsets. It is worth noting that the same
ligand can induce a pro-adhesive signal in one cell type
(Gαi-coupled), and at the same time provide an anti-
adhesive signal in another cell type (Gαs-coupled). For
example, the H4 histamine receptor, selectively expressed
on mast cells and eosinophils, is Gαi-coupled, and could
serve as a chemotactic receptor for these cell types [50].
The Gαs-coupled H2 histamine receptor expressed on
lymphocytes, macrophages and monocytes [51-53] could
provide an anti-adhesive signal. Thus, active down-regula-
tion of integrin affinity through Gαs-coupled GPCRsBMC Immunology 2008, 9:26 http://www.biomedcentral.com/1471-2172/9/26
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might be an essential mechanism regulating trafficking
and selective recruitment of different leukocyte subsets.
Methods
Materials
The VLA-4 specific ligand [6,16,18] 4-((N'-2-methylphe-
nyl)ureido)-phenylacetyl-L-leucyl-L-aspartyl-L-valyl-L-
prolyl-L-alanyl-L-alanyl-L-lysine (LDV containing small
molecule), and its FITC-conjugated analog (LDV-FITC)
were synthesized at Commonwealth Biotechnologies.
Octadecyl rhodamine B chloride (R18), and Indo-1, AM
were from Invitrogen. Restriction enzymes were pur-
chased from New England BioLabs. Human recombinant
CXCL12/SDF-1α was from R&D Systems. Mouse anti-
human CD14/R-PE antibodies, clone UCHM1, and iso-
type control mouse IgG2a/R-PE, clone RPC 5 were from
Ancell Corp. PE mouse anti-human CXCR4 (CD184 PE)
antibodies, clone 12G5, isotype control (mouse IgG2a κ
PE) clone G155-178, PE mouse anti-human formyl pep-
tide receptor, clone 5F1, isotype control (mouse IgG1 κ
PE) clone MOPC-21, PE mouse anti-human CD49d (α4-
integrin subunit PE) clone 9F10 were purchased from BD
Biosciences and used according to manufacturer instruc-
tions. All other reagents were from Sigma-Aldrich. Stock
solutions were prepared in DMSO, at concentrations
~1000 fold higher than the final concentration. Usually, 1
μl of stock solution was added to 1 ml of cell suspension
yielding a final DMSO concentration of 0.1%. Control
samples were treated with equal amount of pure DMSO
(vehicle).
Cell Lines and Transfectant Construct
The human histiocytic lymphoma cell line U937 was pur-
chased from ATCC. Wild type CXCR4 (CD184) receptor
stably transfected U937 cells, and site-directed mutants of
the FPR (non-desensitizing mutant of FPR ΔST) in U937
cells were prepared as described [54] and were a gift of Dr.
Eric Prossnitz (University of New Mexico). High receptor
expressing cells were selected using the MoFlo Flow
Cytometer (DakoCytomation). Cells were grown at 37°C
in a humidified atmosphere of 5% CO2 and 95% air in
RPMI 1640 (supplemented with 2 mM L-glutamine, 100
units/mL penicillin, 100 μg/mL streptomycin, 10 mM
HEPES, pH 7.4, and 10% heat inactivated fetal bovine
serum). Cells were then harvested and resuspended in 1
ml of HEPES buffer (110 mM NaCl, 10 mM KCl, 10 mM
glucose, 1 mM MgCl2, 1.5 mM CaCl2 and 30 mM HEPES,
pH 7.4) containing 0.1% HSA and stored on ice. The
buffer was depleted of lipopolysaccharide by affinity chro-
matography over polymyxin B sepharose (Detoxigel;
Pierce Scientific). Cells were counted using the Coulter
Multisizer/Z2 analyzer (Beckman Coulter). For experi-
ments, cells were suspended in the same HEPES buffer at
1 × 106 cells/ml and warmed to 37°C. Alternatively, cell
were resuspended in serum/dye-free warm RPMI (37°C)
and used immediately.
Purification of human peripheral blood monocytes
Human peripheral blood mononuclear leukocytes were
isolated by density gradient centrifugation. Venous blood
anticoagulated with heparin or EDTA was obtained from
healthy volunteers, and the buffy coat was layered over
Ficoll Hypaque (Amersham Biosciences), and centrifuged
at 1162 g to obtain mononuclear leukocytes. Leukocytes
were washed in 2 mM EDTA in PBS without calcium/mag-
nesium chloride (Gibco), resuspended in RPMI 1640 sup-
plemented with 10% heat-inactivated fetal bovine serum
and used immediately. Monocytes were purified from
mononuclear leukocytes using AutoMACS automated
magnetic cell sorter (Miltenyi Biotec) by negative deple-
tion using magnetic beads with anti-human CD3, CD16,
CD19, CD56 specific antibodies (Miltenyi Biotec) accord-
ing to manufacturer instructions. Purified monocytes
were resuspended in HHB buffer supplemented with
0.1% HSA at 1 × 106 cells/ml and used within 1–3 hours.
Monocyte purity was tested using anti-human CD14 PE
antibodies (clone UCHM1, Ancell Corp.). For LDV-FITC
binding experiments the population of cells was gated on
forward vs. side scatter intensity based on CD14+ cells.
Kinetic Analysis of Binding and Dissociation of VLA-4 
Specific Ligand
Kinetic analysis of the binding and dissociation of the
LDV-FITC probe was described previously [6]. Briefly,
cells (1 × 106 cells/ml) were preincubated in HEPES buffer
containing 0.1% HSA at different conditions for 10–20
min at 37°C. Flow cytometric data were acquired for up to
1024 s at 37°C while the samples were stirred continu-
ously at 300 rpm with a 5 × 2 mm magnetic stir bar (Bel-
Art Products). Samples were analyzed for 30–120 s to
establish a baseline. The fluorescent ligand was added and
acquisition was re-established, creating a 5–10 s gap in the
time course. For real-time affinity activation experiments,
4 nM LDV-FITC was added after establishing a baseline for
unstained cells marked on figures as "autofluorescence".
Then, data were acquired for 2–3 minutes, and cells were
treated with different GPCR ligands at saturating concen-
tration (10 times or higher than Kd). In several experi-
ments cells were treated sequentially with two or more
different compounds. Acquisition was re-established, and
data were acquired continuously for up to 1024 s. The
concentration of the LDV-FITC probe used in the experi-
ments (4 nM) was below the dissociation constant (Kd)
for its binding to resting VLA-4 (low affinity state, Kd~12
nM), and above the Kd for physiologically activated VLA-4
(high affinity state, Kd~1–2 nM) [6]. Therefore, the transi-
tion from the low affinity to the high affinity receptor state
led to increased binding of the probe (from ~25% to ~70–
80% of receptor occupancy, as calculated based on theBMC Immunology 2008, 9:26 http://www.biomedcentral.com/1471-2172/9/26
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one site binding equation), which was detected as an
increase in the mean channel fluorescence (MCF). For
kinetic dissociation measurements, cell samples were pre-
incubated with the fluorescent probe (25 nM), treated
with excess unlabeled LDV containing small molecule (2
μM) and the dissociation of the fluorescent molecule was
followed. The resulting data were converted to MCF versus
time using FCSQuery software developed by Dr. Bruce
Edwards (University of New Mexico).
GPCR ligand concentrations were chosen based upon
known binding affinities [55-60]. Ligands were used at
the concentrations of two or more fold higher than respec-
tive dissociation constants (Kd). This results in more than
66% coverage of the receptor sites. For Gαs-coupled recep-
tor binding site competition experiments (Fig. 2A,B)
lower agonist concentrations were chosen to limit poten-
tial rebinding after addition of a large excess of antagonist
(20 fold or more). The concentrations of antagonists were
chosen based on their respective affinities, to cover more
than 99% of receptor binding sites (200 fold greater than
Kd). By themselves, these high concentrations of Gαs-cou-
pled receptor antagonists did not affect cells activation
after stimulation by Gαi-coupled receptor agonists (see
Fig. 2B, black line).
FRET Detection of VLA-4 Unbending (Extension)
The fluorescence resonance energy transfer (FRET) assay
used the LDV-FITC probe as a donor, which specifically
binds to the α4-integrin headgroup, and octadecyl rhod-
amine B (R18) as an acceptor incorporated into the
plasma membrane was previously described in [18] and
validated in several publications [19,20]. Briefly, U937
cells stably transfected with CXCR4 or the non-desensitiz-
ing mutant (ΔST) of the formyl peptide receptor [33,61],
were preincubated with 100 nM LDV-FITC probe in
HEPES buffer containing 1.5 mM CaCl2, 1 mM MgCl2,
and 0.1% HSA at 37°C. Alternatively, 100 nM LDV-FITC
was added after establishing a baseline for unstained cells
(autofluorescence). Next, samples were analyzed for 1–3
minutes to establish a baseline for 100 nM LDV-FITC, and
then a saturating amount of octadecyl rhodamine B (R18,
10 μM final) was added to yield maximal quenching of
donor fluorescence. 1–3 min after R18 was added; cells
were treated with different GPCR ligands at saturating
concentration (10 times or higher than Kd). In several
experiments cells were treated sequentially with two or
more different compounds as in the LDV-FITC probe
binding experiments. Donor intensities (FL1 in MCF
units) were measured using a Becton-Dickinson FACScan
flow cytometer at 37°C. Changes in the donor fluores-
cence intensity were interpreted as changes in the distance
of closest approach between LDV-FITC ligand binding site
on VLA-4 and the surface of the plasma membrane
[18,19].
Calcium Mobilization
Calcium mobilization in response to ligand stimulation
was measured as described previously [61]. Briefly cells
were harvested by centrifugation, washed, and resus-
pended at 5 × 106 cells/ml in HEPES buffer containing 1.5
mM CaCl2, 1 mM MgCl2. Next, cells were incubated with
5 μM Indo-1, AM for 30 min at 37°C, washed, and resus-
pended at 1 × 106 cells/ml in HEPES buffer, and stored on
ice. Cells were allowed to equilibrate at 37°C for 2 min,
stimulated with different GPCR ligands, and continuous
fluorescence was monitored using a spectrofluorometer
(Photon Technologies International). Excitation at 350
nm, detection at 405 nm and 490 nm. Fluorescence inten-
sity ratio (405 nm/490 nm) was computed in real-time as
a measure of intracellular Ca2+.
Cell Adhesion Assay
The cell suspension adhesion assay has been described
previously [16]. Briefly, U937/ΔST FPR stably transfected
cells were labeled with red fluorescent PKH26GL dye, and
B78H1/VCAM-1 transfectants were stained with green flu-
orescent PKH67GL dye (Sigma-Aldrich). Labeled cells
were washed, resuspended in HEPES buffer supplemented
with 0.1% HSA and stored on ice until used in assays.
Control U937 cells were preincubated with the LDV-con-
taining small molecule for blocking. Prior to data acquisi-
tion, cells were warmed to 37°C for 10 min separately and
then mixed. During data acquisition, the samples were
stirred with a 5 × 2-mm magnetic stir bar (Bel-Art Prod-
ucts, Pequannock, NJ) at 300 rpm and kept at 37°C. For
stimulation, cells were treated with different GPCR lig-
ands at saturating concentration (10 times or higher than
Kd) as described in "Kinetic Analysis of Binding and Dis-
sociation of VLA-4 Specific Ligand". In several experi-
ments cells were treated sequentially with two different
compounds. The number of cell aggregates containing
U937 adherent to B78H1/VCAM-1 (red and green cofluo-
rescent particles) as well as a number of singlets (red or
green fluorescent particles, FL2 and FL1 in FACScan flow
cytometer) were followed in real time. As shown previ-
ously, cell aggregation as detected using cell aggregates
(red and green cofluorescent particles) did not discrimi-
nate between doublets and higher order aggregates [17].
Therefore, the analysis of cell aggregation was done by
using singlet cell depletion methodology [62]. The per-
centage of singlets was calculated as follows: singlets
depletion, % = (number of singlets/(number of aggregates
+ number of singlets)) × 100. Experiments were done
using a FACScan flow cytometer and Cell Quest software
(Becton Dickinson, San Jose, CA). The data were con-
verted to number of singlets/aggregates versus time using
FCSQuery software developed by Dr. Bruce Edwards (Uni-
versity of New Mexico).BMC Immunology 2008, 9:26 http://www.biomedcentral.com/1471-2172/9/26
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Statistical analysis
Curve fits and statistics were performed using GraphPad
Prism (GraphPad). Each experiment was repeated at least
three times. The experimental curves represent the mean
of two or more independent runs. SEM was calculated
using GraphPad Prism.
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6,2'-O-dibutyryladenosine 3',5'-cyclic monophosphate),
fMLFF (N-formyl-L-methionyl-L-leucyl-L-phenylalanyl-L-
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